Journal Article
. 2014 Apr; 74(7):1933-44.
doi: 10.1158/0008-5472.CAN-13-1506.

VISTA Regulates the Development of Protective Antitumor Immunity

Isabelle Le Mercier 1 Wenna Chen  Janet L Lines  Maria Day  Jiannan Li  Petra Sergent  Randolph J Noelle  Li Wang  
  • PMID: 24691994
  •     50 References
  •     168 citations


V-domain Ig suppressor of T-cell activation (VISTA) is a novel negative checkpoint ligand that is homologous to PD-L1 and suppresses T-cell activation. This study demonstrates the multiple mechanisms whereby VISTA relieves negative regulation by hematopoietic cells and enhances protective antitumor immunity. VISTA is highly expressed on myeloid cells and Foxp3(+)CD4(+) regulatory cells, but not on tumor cells within the tumor microenvironment (TME). VISTA monoclonal antibody (mAb) treatment increased the number of tumor-specific T cells in the periphery and enhanced the infiltration, proliferation, and effector function of tumor-reactive T cells within the TME. VISTA blockade altered the suppressive feature of the TME by decreasing the presence of monocytic myeloid-derived suppressor cells and increasing the presence of activated dendritic cells within the tumor microenvironment. In addition, VISTA blockade impaired the suppressive function and reduced the emergence of tumor-specific Foxp3(+)CD4(+) regulatory T cells. Consequently, VISTA mAb administration as a monotherapy significantly suppressed the growth of both transplantable and inducible melanoma. Initial studies explored a combinatorial regimen using VISTA blockade and a peptide-based cancer vaccine with TLR agonists as adjuvants. VISTA blockade synergized with the vaccine to effectively impair the growth of established tumors. Our study therefore establishes a foundation for designing VISTA-targeted approaches either as a monotherapy or in combination with additional immune-targeted strategies for cancer immunotherapy.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
A van Elsas, A A Hurwitz, J P Allison.
J Exp Med, 1999 Aug 03; 190(3). PMID: 10430624    Free PMC article.
Highly Cited.
Immunotherapy earns its spot in the ranks of cancer therapy.
Drew Pardoll, Charles Drake.
J Exp Med, 2012 Feb 15; 209(2). PMID: 22330682    Free PMC article.
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.
Luana Calabrò, Riccardo Danielli, Luca Sigalotti, Michele Maio.
Semin Oncol, 2010 Nov 16; 37(5). PMID: 21074061
The B7 family revisited.
Rebecca J Greenwald, Gordon J Freeman, Arlene H Sharpe.
Annu Rev Immunol, 2005 Mar 18; 23. PMID: 15771580
Highly Cited. Review.
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Manish J Butte, Mary E Keir, +2 authors, Gordon J Freeman.
Immunity, 2007 Jul 17; 27(1). PMID: 17629517    Free PMC article.
Highly Cited.
Cancer-related inflammation.
Alberto Mantovani, Paola Allavena, Antonio Sica, Frances Balkwill.
Nature, 2008 Jul 25; 454(7203). PMID: 18650914
Highly Cited. Review.
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
Christian Blank, Thomas F Gajewski, Andreas Mackensen.
Cancer Immunol Immunother, 2004 Dec 16; 54(4). PMID: 15599732
Highly Cited. Review.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
TLR ligand-peptide conjugate vaccines: toward clinical application.
Gijs G P Zom, Selina Khan, Dmitri V Filippov, Ferry Ossendorp.
Adv Immunol, 2012 Mar 28; 114. PMID: 22449782
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
Christian Blank, Ian Brown, +4 authors, Thomas F Gajewski.
Cancer Res, 2004 Feb 12; 64(3). PMID: 14871849
Highly Cited.
HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma.
Hui Geng, Gui-Mei Zhang, +6 authors, Zuo-Hua Feng.
Int J Cancer, 2006 Jan 21; 118(11). PMID: 16425224
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Axel Hoos, Ramy Ibrahim, +6 authors, Rachel Humphrey.
Semin Oncol, 2010 Nov 16; 37(5). PMID: 21074069
Highly Cited. Review.
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Yoshiko Iwai, Masayoshi Ishida, +3 authors, Nagahiro Minato.
Proc Natl Acad Sci U S A, 2002 Sep 10; 99(19). PMID: 12218188    Free PMC article.
Highly Cited.
Immune system targeting by biodegradable nanoparticles for cancer vaccines.
Joana M Silva, Mafalda Videira, +2 authors, Helena F Florindo.
J Control Release, 2013 Mar 26; 168(2). PMID: 23524187
Myeloid-derived suppressor cells as regulators of the immune system.
Dmitry I Gabrilovich, Srinivas Nagaraj.
Nat Rev Immunol, 2009 Feb 07; 9(3). PMID: 19197294    Free PMC article.
Highly Cited. Review.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
G J Freeman, A J Long, +16 authors, T Honjo.
J Exp Med, 2000 Oct 04; 192(7). PMID: 11015443    Free PMC article.
Highly Cited.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Shari Pilon-Thomas, Amy Mackay, Nasreen Vohra, James J Mulé.
J Immunol, 2010 Mar 03; 184(7). PMID: 20194714    Free PMC article.
Interferon γ limits the effectiveness of melanoma peptide vaccines.
Hyun-Il Cho, Young-Ran Lee, Esteban Celis.
Blood, 2010 Oct 05; 117(1). PMID: 20889921    Free PMC article.
Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects.
Hyun-Il Cho, Esteban Celis.
Cancer Res, 2009 Nov 12; 69(23). PMID: 19903852    Free PMC article.
Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery.
Tomoki Ito, Shino Hanabuchi, +6 authors, Yong-Jun Liu.
Immunity, 2008 Jun 03; 28(6). PMID: 18513999    Free PMC article.
Highly Cited.
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
Li Wang, Rotem Rubinstein, +10 authors, Randolph J Noelle.
J Exp Med, 2011 Mar 09; 208(3). PMID: 21383057    Free PMC article.
Highly Cited.
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
Tyler J Curiel, Shuang Wei, +19 authors, Weiping Zou.
Nat Med, 2003 Apr 22; 9(5). PMID: 12704383
Highly Cited.
Cancer immunotherapy comes of age.
Suzanne L Topalian, George J Weiner, Drew M Pardoll.
J Clin Oncol, 2011 Nov 02; 29(36). PMID: 22042955    Free PMC article.
Highly Cited. Review.
Inhibitory B7-family molecules in the tumour microenvironment.
Weiping Zou, Lieping Chen.
Nat Rev Immunol, 2008 May 27; 8(6). PMID: 18500231
Highly Cited. Review.
Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Eduardo Davila, Richard Kennedy, Esteban Celis.
Cancer Res, 2003 Jun 18; 63(12). PMID: 12810660
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.
Michael A Curran, James P Allison.
Cancer Res, 2009 Sep 10; 69(19). PMID: 19738077    Free PMC article.
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
Annina M Hafner, Blaise Corthésy, Hans P Merkle.
Adv Drug Deliv Rev, 2013 Jun 12; 65(10). PMID: 23751781
Mast cells impair the development of protective anti-tumor immunity.
Anna Wasiuk, Dyana K Dalton, +3 authors, Randolph J Noelle.
Cancer Immunol Immunother, 2012 Jun 12; 61(12). PMID: 22684520    Free PMC article.
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.
Cory L Ahonen, Anna Wasiuk, +7 authors, Randolph J Noelle.
Blood, 2008 Jan 19; 111(6). PMID: 18202224    Free PMC article.
Tumor-specific Th17-polarized cells eradicate large established melanoma.
Pawel Muranski, Andrea Boni, +14 authors, Nicholas P Restifo.
Blood, 2008 Mar 21; 112(2). PMID: 18354038    Free PMC article.
Highly Cited.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Betty Li, Melinda VanRoey, +3 authors, Karin Jooss.
Clin Cancer Res, 2009 Feb 12; 15(5). PMID: 19208793
A molecular perspective of CTLA-4 function.
Wendy A Teft, Mark G Kirchhof, Joaquín Madrenas.
Annu Rev Immunol, 2006 Mar 23; 24. PMID: 16551244
Highly Cited. Review.
A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model.
Jennifer A McWilliams, Sean M McGurran, +2 authors, Ross M Kedl.
J Immunol, 2006 Jun 21; 177(1). PMID: 16785510
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
Fumiya Hirano, Katsumi Kaneko, +9 authors, Lieping Chen.
Cancer Res, 2005 Feb 12; 65(3). PMID: 15705911
Highly Cited.
Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.
Cory L Ahonen, Christie L Doxsee, +6 authors, Ross M Kedl.
J Exp Med, 2004 Mar 10; 199(6). PMID: 15007094    Free PMC article.
Highly Cited.
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.
Loise M Francisco, Victor H Salinas, +4 authors, Arlene H Sharpe.
J Exp Med, 2009 Dec 17; 206(13). PMID: 20008522    Free PMC article.
Highly Cited.
Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Luis Sanchez-Perez, Timothy Kottke, +7 authors, Richard G Vile.
Cancer Res, 2005 Mar 09; 65(5). PMID: 15753401
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells.
Li Wang, Karina Pino-Lagos, +3 authors, Randolph J Noelle.
Proc Natl Acad Sci U S A, 2008 Jul 05; 105(27). PMID: 18599457    Free PMC article.
Highly Cited.
Regulatory T cell lineage specification by the forkhead transcription factor foxp3.
Jason D Fontenot, Jeffrey P Rasmussen, +3 authors, Alexander Y Rudensky.
Immunity, 2005 Mar 23; 22(3). PMID: 15780990
Highly Cited.
CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential.
Shuang Fu, Adam C Yopp, +6 authors, Jonathan S Bromberg.
Am J Transplant, 2003 Dec 18; 4(1). PMID: 14678036
Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma.
Karl S Peggs, Sergio A Quezada.
Expert Rev Anticancer Ther, 2010 Nov 18; 10(11). PMID: 21080797
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Julie R Brahmer, Charles G Drake, +17 authors, Suzanne L Topalian.
J Clin Oncol, 2010 Jun 03; 28(19). PMID: 20516446    Free PMC article.
Highly Cited.
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
David Dankort, David P Curley, +7 authors, Marcus Bosenberg.
Nat Genet, 2009 Mar 14; 41(5). PMID: 19282848    Free PMC article.
Highly Cited.
Coordinated regulation of myeloid cells by tumours.
Dmitry I Gabrilovich, Suzanne Ostrand-Rosenberg, Vincenzo Bronte.
Nat Rev Immunol, 2012 Mar 23; 12(4). PMID: 22437938    Free PMC article.
Highly Cited. Review.
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
J Louise Lines, Lorenzo F Sempere, +2 authors, Randolph Noelle.
Cancer Immunol Res, 2014 Jun 05; 2(6). PMID: 24894088    Free PMC article.
Highly Cited.
Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.
Li Wang, Isabelle Le Mercier, +7 authors, Randolph J Noelle.
Proc Natl Acad Sci U S A, 2014 Oct 01; 111(41). PMID: 25267631    Free PMC article.
Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals.
Preeti Bharaj, Harendra Singh Chahar, +6 authors, Premlata Shankar.
PLoS One, 2014 Oct 04; 9(10). PMID: 25279955    Free PMC article.
Immune escape mechanisms as a guide for cancer immunotherapy.
Gregory L Beatty, Whitney L Gladney.
Clin Cancer Res, 2014 Dec 17; 21(4). PMID: 25501578    Free PMC article.
Highly Cited. Review.
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy.
Joanne Leung, Woong-Kyung Suh.
Immune Netw, 2015 Jan 01; 14(6). PMID: 25550693    Free PMC article.
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.
Padmanee Sharma, James P Allison.
Cell, 2015 Apr 11; 161(2). PMID: 25860605    Free PMC article.
Highly Cited. Review.
Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens.
Dallas B Flies, Tomoe Higuchi, Lieping Chen.
J Immunol, 2015 Apr 29; 194(11). PMID: 25917101    Free PMC article.
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
Jun Liu, Ying Yuan, +8 authors, Li Wang.
Proc Natl Acad Sci U S A, 2015 May 13; 112(21). PMID: 25964334    Free PMC article.
Highly Cited.
Inhibitory receptors as targets for cancer immunotherapy.
Meghan E Turnis, Lawrence P Andrews, Dario A A Vignali.
Eur J Immunol, 2015 May 29; 45(7). PMID: 26018646    Free PMC article.
Selective Involvement of the Checkpoint Regulator VISTA in Suppression of B-Cell, but Not T-Cell, Responsiveness by Monocytic Myeloid-Derived Suppressor Cells from Mice Infected with an Immunodeficiency-Causing Retrovirus.
Kathy A Green, Li Wang, Randolph J Noelle, William R Green.
J Virol, 2015 Jul 15; 89(18). PMID: 26157131    Free PMC article.
Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53.
Kyoung Wan Yoon, Sanguine Byun, +13 authors, Sam W Lee.
Science, 2015 Aug 01; 349(6247). PMID: 26228159    Free PMC article.
Highly Cited.
Combination cancer immunotherapy and new immunomodulatory targets.
Kathleen M Mahoney, Paul D Rennert, Gordon J Freeman.
Nat Rev Drug Discov, 2015 Aug 01; 14(8). PMID: 26228759
Highly Cited. Review.
Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators.
Isabelle Le Mercier, J Louise Lines, Randolph J Noelle.
Front Immunol, 2015 Sep 09; 6. PMID: 26347741    Free PMC article.
Highly Cited. Review.
Advances in immunotherapy for treatment of lung cancer.
Jean G Bustamante Alvarez, María González-Cao, +4 authors, Rafael Rosell.
Cancer Biol Med, 2015 Oct 22; 12(3). PMID: 26487966    Free PMC article.
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.
Amer Assal, Justin Kaner, Gopichand Pendurti, Xingxing Zang.
Immunotherapy, 2015 Nov 17; 7(11). PMID: 26567614    Free PMC article.
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.
Anna Śledzińska, Laurie Menger, +2 authors, Sergio A Quezada.
Mol Oncol, 2015 Nov 19; 9(10). PMID: 26578451    Free PMC article.
Melanoma: oncogenic drivers and the immune system.
Niki Karachaliou, Sara Pilotto, +10 authors, Rafael Rosell.
Ann Transl Med, 2015 Nov 26; 3(18). PMID: 26605311    Free PMC article.
Engineered Materials for Cancer Immunotherapy.
Alexander S Cheung, David J Mooney.
Nano Today, 2015 Dec 08; 10(4). PMID: 26640511    Free PMC article.
Immunosuppressive cells in tumor immune escape and metastasis.
Yang Liu, Xuetao Cao.
J Mol Med (Berl), 2015 Dec 23; 94(5). PMID: 26689709
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.
Gregory T Wurz, Chiao-Jung Kao, Michael W DeGregorio.
Ther Adv Med Oncol, 2016 Jan 12; 8(1). PMID: 26753003    Free PMC article.
Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulation.
Patrícia Oliveira, Joana Carvalho, +9 authors, Carla Oliveira.
Sci Rep, 2016 Oct 11; 6. PMID: 27721458    Free PMC article.
Targeting immune checkpoints in malignant glioma.
Xuhao Zhang, Shan Zhu, +3 authors, Jingtao Chen.
Oncotarget, 2016 Oct 21; 8(4). PMID: 27756892    Free PMC article.
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.
Soumaya Karaki, Marie Anson, +4 authors, Eric Tartour.
Vaccines (Basel), 2016 Nov 10; 4(4). PMID: 27827885    Free PMC article.
VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis.
Sabrina Ceeraz, Petra A Sergent, +4 authors, Randolph J Noelle.
Arthritis Rheumatol, 2016 Dec 20; 69(4). PMID: 27992697    Free PMC article.
A New VISTA on combination therapy for negative checkpoint regulator blockade.
Jie Deng, Isabelle Le Mercier, Anna Kuta, Randolph J Noelle.
J Immunother Cancer, 2016 Dec 30; 4. PMID: 28031817    Free PMC article.
T cell exhaustion: from pathophysiological basics to tumor immunotherapy.
Kemal Catakovic, Eckhard Klieser, Daniel Neureiter, Roland Geisberger.
Cell Commun Signal, 2017 Jan 12; 15(1). PMID: 28073373    Free PMC article.
Highly Cited. Review.
Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment.
Frederick S Varn, Yue Wang, +2 authors, Chao Cheng.
Cancer Res, 2017 Jan 28; 77(6). PMID: 28126714    Free PMC article.
Highly Cited.
Targeting PD-1/PD-L1 in lung cancer: current perspectives.
María González-Cao, Niki Karachaliou, +6 authors, Rafael Rosell.
Lung Cancer (Auckl), 2015 Jul 31; 6. PMID: 28210151    Free PMC article.
Immunoregulatory functions of VISTA.
Elizabeth C Nowak, J Louise Lines, +7 authors, Randolph J Noelle.
Immunol Rev, 2017 Mar 05; 276(1). PMID: 28258694    Free PMC article.
Highly Cited. Review.
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.
Jason Lohmueller, Olivera J Finn.
Pharmacol Ther, 2017 Mar 23; 178. PMID: 28322974    Free PMC article.
Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis.
Na Li, Wenwen Xu, +11 authors, Li Wang.
Sci Rep, 2017 May 05; 7(1). PMID: 28469254    Free PMC article.
The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
Christine Böger, Hans-Michael Behrens, Sandra Krüger, Christoph Röcken.
Oncoimmunology, 2017 May 17; 6(4). PMID: 28507801    Free PMC article.
Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.
Andrew S Flies, Nicholas B Blackburn, +2 authors, Gregory M Woods.
Front Immunol, 2017 May 19; 8. PMID: 28515726    Free PMC article.
Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma.
Carlos A Morales-Betanzos, Hyoungjoo Lee, +4 authors, Daniel C Liebler.
Mol Cell Proteomics, 2017 May 27; 16(10). PMID: 28546465    Free PMC article.
New B7 Family Checkpoints in Human Cancers.
Ling Ni, Chen Dong.
Mol Cancer Ther, 2017 Jul 07; 16(7). PMID: 28679835    Free PMC article.
Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability.
Qi Wang, Jianwei He, +2 authors, Lieping Chen.
Sci Rep, 2017 Jul 22; 7(1). PMID: 28729608    Free PMC article.
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.
Hojabr Kakavand, Louise A Jackett, +7 authors, Richard A Scolyer.
Mod Pathol, 2017 Aug 05; 30(12). PMID: 28776578
VISTA.COMP - an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses.
Aaron Prodeus, Aws Abdul-Wahid, +9 authors, Jean Gariépy.
JCI Insight, 2017 Sep 22; 2(18). PMID: 28931757    Free PMC article.
Cardiotoxicity of immune checkpoint inhibitors.
Gilda Varricchi, Maria Rosaria Galdiero, +5 authors, Carlo Gabriele Tocchetti.
ESMO Open, 2017 Nov 07; 2(4). PMID: 29104763    Free PMC article.
Highly Cited. Review.
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.
Franz Villarroel-Espindola, Xiaoqing Yu, +9 authors, Kurt A Schalper.
Clin Cancer Res, 2017 Dec 06; 24(7). PMID: 29203588    Free PMC article.
VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.
Sabrina Ceeraz, Susan K Eszterhas, +9 authors, Roy A Fava.
Arthritis Res Ther, 2017 Dec 09; 19(1). PMID: 29216931    Free PMC article.
The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.
Wenwen Xu, TạMinh Hiếu, Subramaniam Malarkannan, Li Wang.
Cell Mol Immunol, 2018 Jan 30; 15(5). PMID: 29375120    Free PMC article.
Next generation of immune checkpoint therapy in cancer: new developments and challenges.
Julian A Marin-Acevedo, Bhagirathbhai Dholaria, +3 authors, Yanyan Lou.
J Hematol Oncol, 2018 Mar 17; 11(1). PMID: 29544515    Free PMC article.
Highly Cited. Review.
β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.
Jérémie Nsengimana, Jon Laye, +15 authors, Julia Newton-Bishop.
J Clin Invest, 2018 Apr 18; 128(5). PMID: 29664013    Free PMC article.
VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.
Ming Zhang, Hua-Jin Pang, +4 authors, Xiao-Feng He.
BMC Cancer, 2018 May 04; 18(1). PMID: 29720116    Free PMC article.
Immunomodulatory Function of Myeloid-Derived Suppressor Cells during B Cell-Mediated Immune Responses.
Bilgenaz Özkan, Heejin Lim, Sung-Gyoo Park.
Int J Mol Sci, 2018 May 16; 19(5). PMID: 29762501    Free PMC article.
Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
Nicholas Borcherding, Ryan Kolb, +3 authors, Weizhou Zhang.
J Mol Biol, 2018 May 26; 430(14). PMID: 29800567    Free PMC article.
Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.
Hauke Stamm, Felix Klingler, +16 authors, Walter Fiedler.
Oncogene, 2018 Jun 02; 37(39). PMID: 29855615    Free PMC article.
Next generation immune-checkpoints for cancer therapy.
Chiara Donini, Lorenzo D'Ambrosio, +2 authors, Dario Sangiolo.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951308    Free PMC article.
Emerging strategies for combination checkpoint modulators in cancer immunotherapy.
Aleksandra Popovic, Elizabeth M Jaffee, Neeha Zaidi.
J Clin Invest, 2018 Aug 02; 128(8). PMID: 30067248    Free PMC article.
Highly Cited. Review.
Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer.
Hong Liao, Hongmei Zhu, Shanling Liu, He Wang.
Oncol Lett, 2018 Aug 22; 16(3). PMID: 30127950    Free PMC article.
Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
Daniela Cornelia Lazăr, Mihaela Flavia Avram, +3 authors, Adrian Goldiș.
World J Gastroenterol, 2018 Sep 01; 24(32). PMID: 30166856    Free PMC article.
Highly Cited. Review.
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.
Nicolas Villanueva, Lyudmila Bazhenova.
Ther Adv Respir Dis, 2018 Sep 15; 12. PMID: 30215300    Free PMC article.
VSIG-3 as a ligand of VISTA inhibits human T-cell function.
Jinghua Wang, Guoping Wu, +17 authors, Vassilios Kalabokis.
Immunology, 2018 Sep 17; 156(1). PMID: 30220083    Free PMC article.
Highly Cited.
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.
Liru Wang, Bei Jia, +9 authors, Hong Zheng.
Oncoimmunology, 2018 Sep 20; 7(9). PMID: 30228937    Free PMC article.
Not All Immune Checkpoints Are Created Equal.
Annika De Sousa Linhares, Judith Leitner, Katharina Grabmeier-Pfistershammer, Peter Steinberger.
Front Immunol, 2018 Sep 21; 9. PMID: 30233564    Free PMC article.
Highly Cited. Review.
Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression.
Chloé Laplagne, Marcin Domagala, +7 authors, Mary Poupot.
Int J Mol Sci, 2019 Sep 25; 20(19). PMID: 31547627    Free PMC article.
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Shuang Qin, Linping Xu, +3 authors, Suxia Luo.
Mol Cancer, 2019 Nov 07; 18(1). PMID: 31690319    Free PMC article.
Highly Cited. Review.
Effects of Human Adipose Tissue-Derived and Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in a Dextran Sulfate Sodium-Induced Mouse Model.
Shunzo Ikarashi, Atsunori Tsuchiya, +8 authors, Shuji Terai.
Biores Open Access, 2019 Nov 14; 8(1). PMID: 31720090    Free PMC article.
Check Point Inhibitors and Their Role in Immunosuppression in Sepsis.
Michelle E Wakeley, Chyna C Gray, +2 authors, Alfred Ayala.
Crit Care Clin, 2019 Nov 18; 36(1). PMID: 31733683    Free PMC article.
Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness.
Thomas W K Broughton, Mohamed A ElTanbouly, +10 authors, J Louise Lines.
Front Immunol, 2019 Dec 06; 10. PMID: 31803182    Free PMC article.
Structural insight into T cell coinhibition by PD-1H (VISTA).
Benjamin T Slater, Xue Han, Lieping Chen, Yong Xiong.
Proc Natl Acad Sci U S A, 2020 Jan 11; 117(3). PMID: 31919279    Free PMC article.
FOXD3 Regulates VISTA Expression in Melanoma.
Sheera R Rosenbaum, Meghan Knecht, +11 authors, Andrew E Aplin.
Cell Rep, 2020 Jan 16; 30(2). PMID: 31940493    Free PMC article.
Reverting Immune Suppression to Enhance Cancer Immunotherapy.
Bella S Guerrouahen, Cristina Maccalli, +2 authors, Emmanuel T Akporiaye.
Front Oncol, 2020 Feb 11; 9. PMID: 32039024    Free PMC article.
Potential value of V-domain Ig suppressor of T-cell activation for assessing progn osis in cervical cancer and as a target for therapy.
Ledi Kuang, Yuedong He.
Int J Clin Exp Pathol, 2020 Feb 15; 13(1). PMID: 32055269    Free PMC article.
Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis.
Xin-Lin He, Ying Zhou, +2 authors, Zhi Wang.
Sci Rep, 2020 Feb 16; 10(1). PMID: 32060343    Free PMC article.
Systematic Review.
Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
Wenwen Xu, Juan Dong, +10 authors, Li Wang.
Cancer Immunol Res, 2019 Jul 26; 7(9). PMID: 31340983    Free PMC article.
T lymphocyte-targeted immune checkpoint modulation in glioma.
William James Kelly, Amber Jin Giles, Mark Gilbert.
J Immunother Cancer, 2020 Feb 14; 8(1). PMID: 32051289    Free PMC article.
Therapeutic cancer vaccine: building the future from lessons of the past.
T Tran, C Blanc, +3 authors, Eric Tartour.
Semin Immunopathol, 2018 Jul 07; 41(1). PMID: 29978248
VISTA expressed in tumour cells regulates T cell function.
Kumuluzi Mulati, Junzo Hamanishi, +14 authors, Masaki Mandai.
Br J Cancer, 2018 Nov 02; 120(1). PMID: 30382166    Free PMC article.
CD71+VISTA+ erythroid cells promote the development and function of regulatory T cells through TGF-β.
Shima Shahbaz, Najmeh Bozorgmehr, +4 authors, Shokrollah Elahi.
PLoS Biol, 2018 Dec 15; 16(12). PMID: 30550561    Free PMC article.
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Yongshuai Jiang, Ming Chen, Hong Nie, Yuanyang Yuan.
Hum Vaccin Immunother, 2019 Mar 20; 15(5). PMID: 30888929    Free PMC article.
Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Jie Deng, Jiannan Li, +12 authors, Rodwell Mabaera.
Cancer Immunol Res, 2019 May 16; 7(7). PMID: 31088847    Free PMC article.
Highly Cited.
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.
Jorge Blando, Anu Sharma, +20 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2019 Jan 13; 116(5). PMID: 30635425    Free PMC article.
Highly Cited.
VISTA: Coming of age as a multi-lineage immune checkpoint.
M A ElTanbouly, E Schaafsma, R J Noelle, J L Lines.
Clin Exp Immunol, 2020 Jan 14; 200(2). PMID: 31930484    Free PMC article.
Immunotherapy in Renal Cell Carcinoma: The Future Is Now.
Antoine Deleuze, Judikaël Saout, +9 authors, Solène-Florence Kammerer-Jacquet.
Int J Mol Sci, 2020 Apr 09; 21(7). PMID: 32260578    Free PMC article.
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies.
Alberto Puccini, Francesca Battaglin, +2 authors, Mohamed E Salem.
J Immunother Cancer, 2020 May 13; 8(1). PMID: 32393474    Free PMC article.
VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
Mohamed A ElTanbouly, Walburga Croteau, Randolph J Noelle, J Louise Lines.
Semin Immunol, 2019 Oct 13; 42. PMID: 31604531    Free PMC article.
Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
Zi Mei, Junwen Huang, Bin Qiao, Alfred King-Yin Lam.
Int J Oral Sci, 2020 May 29; 12(1). PMID: 32461587    Free PMC article.
Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.
Kristian M Hargadon.
Clin Transl Med, 2020 Jun 09; 10(1). PMID: 32508018    Free PMC article.
Novel Targets for the Treatment of Melanoma.
Lara Ambrosi, Shaheer Khan, Richard D Carvajal, Jessica Yang.
Curr Oncol Rep, 2019 Nov 07; 21(11). PMID: 31696329
New emerging targets in cancer immunotherapy: the role of VISTA.
Marco Tagliamento, Paolo Bironzo, Silvia Novello.
ESMO Open, 2020 Jun 20; 4(Suppl 3). PMID: 32554470    Free PMC article.
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy.
Xing Huang, Xiaozhen Zhang, +5 authors, Tingbo Liang.
J Hematol Oncol, 2020 Jul 01; 13(1). PMID: 32600443    Free PMC article.
Advances in targeted therapy for malignant lymphoma.
Li Wang, Wei Qin, +5 authors, Wei-Li Zhao.
Signal Transduct Target Ther, 2020 Apr 17; 5(1). PMID: 32296035    Free PMC article.
Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors.
Diwakar Davar, Hassane M Zarour.
Methods Mol Biol, 2019 Sep 11; 2055. PMID: 31502146    Free PMC article.
Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure.
Selena Vigano, Sara Bobisse, +2 authors, Alexandre Harari.
Front Immunol, 2020 Jul 28; 11. PMID: 32714330    Free PMC article.
VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance.
Mohamed A ElTanbouly, Yanding Zhao, +19 authors, Randolph J Noelle.
Science, 2020 Jan 18; 367(6475). PMID: 31949051    Free PMC article.
Immunotherapies and Combination Strategies for Immuno-Oncology.
Cody Barbari, Tyler Fontaine, +4 authors, Rahul R Deshmukh.
Int J Mol Sci, 2020 Jul 19; 21(14). PMID: 32679922    Free PMC article.
Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy.
Lukas Amon, Lukas Hatscher, +2 authors, Christian H K Lehmann.
Pharmaceutics, 2020 Jul 18; 12(7). PMID: 32674488    Free PMC article.
Scientifically based combination therapies with immuno-oncology checkpoint inhibitors.
Hui Yi Chew, Riccardo Dolcetti, Fiona Simpson.
Br J Clin Pharmacol, 2020 May 07; 86(9). PMID: 32372470    Free PMC article.
Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?
Geoffrey Alan Watson, Jeffrey Doi, Aaron Richard Hansen, Anna Spreafico.
Br J Clin Pharmacol, 2020 May 13; 86(9). PMID: 32394468    Free PMC article.
Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies.
Anita Mazloom, Nima Ghalehsari, +5 authors, Uqba Khan.
J Clin Med, 2020 Aug 13; 9(8). PMID: 32781500    Free PMC article.
The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression.
Jae Won Choi, Young Jae Kim, +5 authors, Woo Jin Lee.
Sci Rep, 2020 Sep 03; 10(1). PMID: 32873829    Free PMC article.
Immunotherapy in extensive small cell lung cancer.
Vaibhav Verma, Geeti Sharma, Abhijai Singh.
Exp Hematol Oncol, 2019 Feb 12; 8. PMID: 30740266    Free PMC article.
VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy.
Juan-Manuel Hernandez-Martinez, Edgar Vergara, +2 authors, Oscar Arrieta.
J Thorac Dis, 2019 Feb 13; 10(12). PMID: 30746169    Free PMC article.
Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates.
Manpreet Sambi, Leila Bagheri, Myron R Szewczuk.
J Oncol, 2019 Apr 04; 2019. PMID: 30941175    Free PMC article.
Highly Cited. Review.
Dendritic Cells and Cancer: From Biology to Therapeutic Intervention.
Ben Wylie, Christophe Macri, Justine D Mintern, Jason Waithman.
Cancers (Basel), 2019 Apr 14; 11(4). PMID: 30979057    Free PMC article.
The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma.
Heike Loeser, Max Kraemer, +9 authors, Alexander Quaas.
Oncoimmunology, 2019 May 10; 8(5). PMID: 31069143    Free PMC article.
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review.
Yolla Haibe, Ziad El Husseini, Rola El Sayed, Ali Shamseddine.
Int J Mol Sci, 2020 Sep 02; 21(17). PMID: 32867025    Free PMC article.
Systematic Review.
An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA.
Nishant Mehta, Sainiteesh Maddineni, +8 authors, Jennifer R Cochran.
Sci Rep, 2020 Sep 18; 10(1). PMID: 32938950    Free PMC article.
Exploring the VISTA of microglia: immune checkpoints in CNS inflammation.
Malte Borggrewe, Susanne M Kooistra, +2 authors, Jon D Laman.
J Mol Med (Berl), 2020 Aug 29; 98(10). PMID: 32856125    Free PMC article.
Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy.
Yufei Wang, Anna Jia, +5 authors, Guangwei Liu.
Cancers (Basel), 2020 Sep 19; 12(9). PMID: 32942545    Free PMC article.
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.
Yunlong Jia, Lihua Liu, Baoen Shan.
Ann Transl Med, 2020 Nov 05; 8(17). PMID: 33145314    Free PMC article.
Alternative Checkpoints as Targets for Immunotherapy.
Ayush Pant, Ravi Medikonda, Michael Lim.
Curr Oncol Rep, 2020 Nov 04; 22(12). PMID: 33141349    Free PMC article.
Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.
Karsten A Pilones, Michal Hensler, +5 authors, Silvia C Formenti.
Oncoimmunology, 2020 Nov 06; 9(1). PMID: 33150045    Free PMC article.
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Negar Hosseinkhani, Afshin Derakhshani, +9 authors, Behzad Baradaran.
Int J Mol Sci, 2020 Nov 11; 21(21). PMID: 33167514    Free PMC article.
Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma.
Claudia Ceci, Maria Grazia Atzori, Pedro Miguel Lacal, Grazia Graziani.
Cancers (Basel), 2020 Nov 21; 12(11). PMID: 33212945    Free PMC article.
The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xiaoxue Xie, Junying Zhang, +8 authors, Jun Liu.
Front Immunol, 2020 Dec 01; 11. PMID: 33250890    Free PMC article.
Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects.
Long Long, Chen Zhao, +3 authors, Honglei Chen.
Clin Drug Investig, 2019 Feb 20; 39(4). PMID: 30778885
VISTA is an acidic pH-selective ligand for PSGL-1.
Robert J Johnston, Linhui Julie Su, +33 authors, Alan J Korman.
Nature, 2019 Oct 28; 574(7779). PMID: 31645726
Emerging immunotherapies for metastasis.
Sarah C Edwards, Wilma H M Hoevenaar, Seth B Coffelt.
Br J Cancer, 2020 Dec 03; 124(1). PMID: 33262520    Free PMC article.
LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
Nora Wuerdemann, Katharina Pütz, +12 authors, Jens P Klussmann.
Int J Mol Sci, 2021 Jan 06; 22(1). PMID: 33396515    Free PMC article.
Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer.
Zelin Hou, Yu Pan, +8 authors, Heguang Huang.
J Cancer Res Clin Oncol, 2020 Nov 26; 147(2). PMID: 33237432    Free PMC article.
The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment.
Maximilian Haist, Henner Stege, Stephan Grabbe, Matthias Bros.
Cancers (Basel), 2021 Jan 13; 13(2). PMID: 33430105    Free PMC article.
Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression.
Yu Mei, Wenya Linda Bi, +8 authors, Ian F Dunn.
Pituitary, 2021 Jan 26; 24(3). PMID: 33492612
VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer.
Xi Cao, Xinyu Ren, +4 authors, Qiang Sun.
Front Oncol, 2021 Jan 29; 10. PMID: 33505908    Free PMC article.
Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients.
Arutha Kulasinghe, Touraj Taheri, +3 authors, Chamindie Punyadeera.
Front Oncol, 2021 Feb 06; 10. PMID: 33542903    Free PMC article.
V-domain Ig suppressor of T cell activation (VISTA) inhibition is a new approach to cancer therapy: a Bibliometric study.
Oum Kaltoum Ait Boujmia.
Naunyn Schmiedebergs Arch Pharmacol, 2021 Feb 23; 394(6). PMID: 33616679
Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Xidan Gao, Hongshu Sui, +3 authors, Peng Qu.
Front Immunol, 2021 Feb 23; 11. PMID: 33613512    Free PMC article.
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy.
Yu Yuan, Abdalla Adam, Chen Zhao, Honglei Chen.
Cancers (Basel), 2021 Feb 11; 13(4). PMID: 33562324    Free PMC article.
VISTA: A Target to Manage the Innate Cytokine Storm.
Mohamed A ElTanbouly, Yanding Zhao, +4 authors, Randolph J Noelle.
Front Immunol, 2021 Mar 02; 11. PMID: 33643285    Free PMC article.
Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma.
Anjali Rohatgi, John M Kirkwood.
Front Oncol, 2021 Mar 19; 11. PMID: 33732652    Free PMC article.
Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer.
Won Ik Seo, Chan Ho Lee, +6 authors, Inhak Choi.
Cancer Immunol Immunother, 2021 Mar 27; 70(11). PMID: 33770210
Structural Basis of VSIG3: The Ligand for VISTA.
Xiaoxue Xie, Caiping Chen, +5 authors, Jun Liu.
Front Immunol, 2021 Apr 13; 12. PMID: 33841409    Free PMC article.
VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
Long Yuan, Jahnavi Tatineni, Kathleen M Mahoney, Gordon J Freeman.
Trends Immunol, 2021 Jan 27; 42(3). PMID: 33495077    Free PMC article.
Terminating Cancer by Blocking VISTA as a Novel Immunotherapy: Hasta la vista, baby.
Ji-Eun Irene Yum, Young-Kwon Hong.
Front Oncol, 2021 May 04; 11. PMID: 33937071    Free PMC article.
Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma.
H Barber, A Tofias, +7 authors, K M Kurian.
J Oncol, 2021 May 18; 2021. PMID: 33995529    Free PMC article.
Clinical Insights Into Novel Immune Checkpoint Inhibitors.
Jii Bum Lee, Sang-Jun Ha, Hye Ryun Kim.
Front Pharmacol, 2021 May 25; 12. PMID: 34025438    Free PMC article.
FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Minlin Jiang, Chunyan Wu, +13 authors, Caicun Zhou.
J Immunother Cancer, 2021 May 20; 9(5). PMID: 34006632    Free PMC article.
V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma.
Pim Mutsaers, Hayri E Balcioglu, +9 authors, Reno Debets.
Cancers (Basel), 2021 Jun 03; 13(9). PMID: 34066382    Free PMC article.
The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
Negar Hosseinkhani, Afshin Derakhshani, +7 authors, Behzad Baradaran.
Front Immunol, 2021 Jun 08; 12. PMID: 34093577    Free PMC article.
Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies.
Yara Abdou, Manu Pandey, +3 authors, Marc S Ernstoff.
Br J Clin Pharmacol, 2020 Apr 24; 86(9). PMID: 32323342    Free PMC article.
VISTA is an activating receptor in human monocytes.
Bryan M Rogers, Laura Smith, +14 authors, Gabriel R Starbeck-Miller.
J Exp Med, 2021 Jun 10; 218(8). PMID: 34106206    Free PMC article.
Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
Kristin C Hicks, Karin M Knudson, +9 authors, Sofia R Gameiro.
Clin Cancer Res, 2019 Oct 28; 26(3). PMID: 31645354    Free PMC article.
Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer.
Violet Y Tu, Asma Ayari, Roddy S O'Connor.
Antibodies (Basel), 2021 Jul 03; 10(3). PMID: 34203136    Free PMC article.
PD-1 and beyond to Activate T Cells in Cutaneous Squamous Cell Cancers: The Case for 4-1BB and VISTA Antibodies in Combination Therapy.
Quentin Wright, Jazmina L Gonzalez Cruz, James W Wells, Graham R Leggatt.
Cancers (Basel), 2021 Jul 21; 13(13). PMID: 34282763    Free PMC article.
Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.
Maureen L Drakes, Patrick J Stiff.
Adv Exp Med Biol, 2021 Aug 03; 1330. PMID: 34339029
High-Affinity Anti-VISTA Antibody Protects against Sepsis by Inhibition of T Lymphocyte Apoptosis and Suppression of the Inflammatory Response.
Tianzhu Tao, Lulong Bo, +7 authors, Guorong Zhang.
Mediators Inflamm, 2021 Aug 10; 2021. PMID: 34366711    Free PMC article.
Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
Guoying Zhou, Patrick P C Boor, +2 authors, Jaap Kwekkeboom.
Br J Cancer, 2021 Aug 18; 126(1). PMID: 34400801    Free PMC article.
B7-H5 blockade enhances CD8+ T-cell-mediated antitumor immunity in colorectal cancer.
Jiayu Wang, Hongya Wu, +9 authors, Tongguo Shi.
Cell Death Discov, 2021 Sep 20; 7(1). PMID: 34537815    Free PMC article.
Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle.
Aikaterini Hatzioannou, Athina Boumpas, +4 authors, Panayotis Verginis.
Front Immunol, 2021 Sep 21; 12. PMID: 34539668    Free PMC article.
Immune Checkpoints in Cancers: From Signaling to the Clinic.
Céline Pisibon, Amira Ouertani, +2 authors, Yann Cheli.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572799    Free PMC article.
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
Kai Li, Houhui Shi, +6 authors, Yongsheng Wang.
Signal Transduct Target Ther, 2021 Oct 09; 6(1). PMID: 34620838    Free PMC article.
Myeloid Cells Are Enriched in Tonsillar Crypts, Providing Insight into the Viral Tropism of Human Papillomavirus.
Austin K Mattox, Jessica Roelands, +13 authors, Sara I Pai.
Am J Pathol, 2021 Jul 26; 191(10). PMID: 34303699    Free PMC article.
The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment.
Nadia Bolandi, Afshin Derakhshani, +7 authors, Behzad Baradaran.
Int J Mol Sci, 2021 Oct 14; 22(19). PMID: 34639059    Free PMC article.
Expression and clinicopathological significance of Foxp3 and VISTA in cervical cancer.
Li Li, Xiao-Ting Xu, +2 authors, Ju-Ying Zhou.
Am J Transl Res, 2021 Oct 16; 13(9). PMID: 34650712    Free PMC article.
VISTA Blockade Aggravates Bone Loss in Experimental Murine Apical Periodontitis.
Fuhua Yang, Yifei Zhang, Zhi Chen, Lu Zhang.
Front Immunol, 2021 Oct 26; 12. PMID: 34691045    Free PMC article.
The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.
Amina Ghouzlani, Abdelhakim Lakhdar, +2 authors, Abdallah Badou.
Sci Rep, 2021 Nov 04; 11(1). PMID: 34728682    Free PMC article.
VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes.
Andreia Gameiro, Catarina Nascimento, Jorge Correia, Fernando Ferreira.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771722    Free PMC article.
Agonistic nanobodies and antibodies to human VISTA.
Yu-Heng Vivian Ma, Amanda Sparkes, +2 authors, Jean Gariépy.
MAbs, 2021 Nov 25; 13(1). PMID: 34818120    Free PMC article.
PD-1H Expression Associated With CD68 Macrophage Marker Confers an Immune-Activated Microenvironment and Favorable Overall Survival in Human Esophageal Squamous Cell Carcinoma.
Yuangui Chen, Rui Feng, +4 authors, Qiuyu Zhang.
Front Mol Biosci, 2021 Dec 25; 8. PMID: 34950702    Free PMC article.
The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1.
Hongzhong Li, Yi Xiao, +17 authors, Dihua Yu.
Cancer Cell, 2021 Nov 26; 40(1). PMID: 34822775    Free PMC article.
Effect of CMNa combined with radiotherapy on the tumor immune microenvironment of mouse cervical cancer cell transplantation tumor model.
Li Li, Weiqiang Shi, Juying Zhou.
Bioengineered, 2021 Apr 01; 12(1). PMID: 33784955    Free PMC article.
Antitumor effects of targeting myeloid-derived suppressive cells.
Dong Zeng, Haixia Long, Bo Zhu.
Transl Cancer Res, 2020 Sep 01; 9(9). PMID: 35117939    Free PMC article.
Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.
Xunrui Chen, Wenhui Zhang, +2 authors, Feng Liu.
Aging (Albany NY), 2022 Jan 18; 14(2). PMID: 35037899    Free PMC article.
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity.
Adrià Archilla-Ortega, Carla Domuro, Juan Martin-Liberal, Purificación Muñoz.
J Exp Clin Cancer Res, 2022 Feb 16; 41(1). PMID: 35164813    Free PMC article.
Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
Dipti Thakkar, Shalini Paliwal, +9 authors, Jerome D Boyd-Kirkup.
J Immunother Cancer, 2022 Feb 09; 10(2). PMID: 35131861    Free PMC article.
Ablation of T cell-associated PD-1H enhances functionality and promotes adoptive immunotherapy.
Li Hu, Ling Chen, +7 authors, Lieping Chen.
JCI Insight, 2021 Dec 15; 7(2). PMID: 34905507    Free PMC article.
Identification of an EMT-related lncRNA signature and LINC01116 as an immune-related oncogene in hepatocellular carcinoma.
Haisu Tao, Yuxin Zhang, +8 authors, Erlei Zhang.
Aging (Albany NY), 2022 Feb 12; 14(3). PMID: 35148283    Free PMC article.
Negative Immune Checkpoint Protein, VISTA, Regulates the CD4+ Treg Population During Sepsis Progression to Promote Acute Sepsis Recovery and Survival.
Chyna C Gray, Bethany Biron-Girard, +5 authors, Alfred Ayala.
Front Immunol, 2022 Apr 12; 13. PMID: 35401514    Free PMC article.
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.
Lawrence P Andrews, Hiroshi Yano, Dario A A Vignali.
Nat Immunol, 2019 Oct 16; 20(11). PMID: 31611702
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.
Daniel Ronen, Aseel Bsoul, +4 authors, Rabea Asleh.
Vaccines (Basel), 2022 Apr 24; 10(4). PMID: 35455289    Free PMC article.
Identify the Prognostic and Immune Profile of VSIR in the Tumor Microenvironment: A Pan-Cancer Analysis.
Yuanyuan Liu, Jingwei Zhang, +12 authors, Quan Cheng.
Front Cell Dev Biol, 2022 May 03; 10. PMID: 35493077    Free PMC article.
Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials.
Bharat Goel, Anoop Kumar Tiwari, +5 authors, Arun Khattri.
Transl Oncol, 2022 Apr 24; 21. PMID: 35460943    Free PMC article.
Metformin attenuates V-domain Ig suppressor of T-cell activation through the aryl hydrocarbon receptor pathway in Melanoma: In Vivo and In Vitro Studies.
Fawaz E Alanazi, Homood M As Sobeai, +6 authors, Ali Alhoshani.
Saudi Pharm J, 2022 May 10; 30(2). PMID: 35528855    Free PMC article.
Lag3: From Bench to Bedside.
Francesca Aroldi, Reem Saleh, +3 authors, Mark R Middleton.
Cancer Treat Res, 2022 May 14; 183. PMID: 35551660
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape.
Qinghua Wu, Li You, +4 authors, Vojtech Adam.
J Hematol Oncol, 2022 Jun 07; 15(1). PMID: 35659268